Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

Flagship Biosciences Acquires Interpace Pharma Solutions from Interpace Biosciences

September 1, 2022

Healthcare Services

Flagship Biosciences has acquired Interpace Pharma Solutions (IPS), a division of Interpace Biosciences, expanding Flagship's molecular pathology, cytogenetics, genomics and biomarker analytics capabilities. The deal follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies and adds a state-of-the-art laboratory in Research Triangle Park, North Carolina to Flagship's service offering.

1315 Capital and Ampersand Capital Partners Invest $20M in Interpace Biosciences

January 13, 2020

Healthcare Services

Interpace Biosciences entered into an agreement for a $20 million Series B Preferred Stock investment — $19 million from 1315 Capital and $1 million from existing investor Ampersand Capital Partners. The financing (and a coincident one-for-ten reverse stock split) is intended to help Interpace reach cash-flow break-even, accelerate growth and pursue acquisitions; Ampersand also exchanged its Series A preferred for the new Series B shares.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.

Pace Life Sciences Acquires Biopharma Global

September 8, 2022

Healthcare Services

Pace Life Sciences, a CDMO subsidiary of Pace, has acquired Biopharma Global, a Vienna, Virginia-based regulatory affairs consultancy that specializes in orphan and other high‑unmet‑need drug regulatory support. The acquisition expands Pace's regulatory strategy and submission capabilities for FDA and EMA filings, strengthening its end-to-end development and regulatory services for biotech and pharmaceutical clients.

Ampersand Capital Partners Completes Growth Equity Investment in GenDx

May 8, 2019

Biotechnology

Ampersand Capital Partners completed a minority growth equity investment in Genome Diagnostics B.V. (GenDx), a Utrecht-based provider of molecular diagnostic kits and analysis software for transplantation and companion diagnostics. The partnership will support GenDx's organic growth and M&A strategy; Ampersand's David Parker and Operating Partner Mike Evans joined GenDx's board.

Labcorp Acquires Personal Genome Diagnostics (PGDx)

February 21, 2022

Healthcare Services

Labcorp completed its acquisition of Personal Genome Diagnostics (PGDx), a cancer genomics company that develops liquid biopsy and tissue-based NGS products. Labcorp paid $450 million in cash at closing plus up to $125 million in performance-based milestones to expand its oncology genomics and liquid biopsy capabilities and accelerate access to precision diagnostics for clinical care and trials.